A phase IIb study of GS-6624 in subjects with compensated cirrhosis

• Research type

  Research Study

• Full title

  A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

• IRAS ID

  115293

• Contact name

  William Rosenberg

• Contact email

  w.rosenberg@ucl.ac.uk

• Sponsor organisation

  Gilead Sciences Inc.

• Eudract number

  2012-002489-11

• Clinicaltrials.gov Identifier

  NCT01672879

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0249

• Date of REC Opinion

  19 Jun 2013

• REC opinion

  Further Information Favourable Opinion